Joseph Chao

GI medical oncologist. Tweets are my own opinions. RTs are not representative of commercial endorsement.

[CURE Today @cure_today]

Want to learn more about #stomachcancer? Join @StoCANcer in this webinar where @KlempnerSam @rutikamehtaMD @Yanghee61217641 and special speaker from the #FDA de-mystify the clinical trial process & highlight different clinical trials. Register today: https://t.co/5aSKmsiwXP

[Joseph Chao @JoeChaoMD]

Happy to catch up with @KlempnerSam and @sundar__raghav at latest @ISSPP1 conference in SoCal #palmtrees lending their expertise on research directions to advance treatment of #stomachcancer peritoneal mets

[Joseph Chao @JoeChaoMD]

@DrRaviSalgia Thank you @DrRaviSalgia and all my @COHMedOnc @cityofhope colleagues for the many years of mentorship, inspiration, and collegiality to make possible my next new adventure. Looking forward as well to continue working together on new breakthroughs #CancerResearch #clinicaltrials

[Dr. Cathy Eng @CathyEngMD]

Updates from @myESMO from Dr. Van Cutsem @UZLeuven re: new guidelines for #UGI #cancers #CancerResearch #clinicalresearch @GreatDebatesCME #GDUGI2022

[Dr. Cathy Eng @CathyEngMD]

Happening now! The expertise on #rarecancers with Drs. Demetri, Magge, Bergland focusing on #sarcoma #NET #appendiceal #cancers as well as nuances in early stage with @pashtoonkasi #coloncancer @GreatDebatesCME #GDUGI2022 #cancerresearch

[OLN Great Debates in Solid Tumors @OLNGreatDebates]

Attendees are loving #GDUGI2022. Thank you to our amazing faculty and Conference Chairs! @CathyEngMD @ILSONDavid There is still time to join us. Sign up here: https://t.co/lLq7f5FLVw

[Dr. Cathy Eng @CathyEngMD]

Great overview from @JoeChaoMD @cityofhope on novel agents in #UGI #cancers. @GreatDebatesCME #GDUGI2022 #cancerreserch #clincialtrials #stomach #CANCER
https://t.co/x4uY3Nt5F3

[Dr. Cathy Eng @CathyEngMD]

Join us for virtual @GreatDebatesCME #GDUGI2022 for #uppergicancer w/ @ILSONDavid @aparna1024 @JoeChaoMD re: role of #XRT #newagents #ctDNA. #CancerResearch #CANCER #clinicaltrials @cityofhope @MSKCancerCenter @MGHCancerCenter @VUMC_Cancer https://t.co/x4uY3Nt5F3

[Dr. Cathy Eng @CathyEngMD]

#ESMO22 Codebreak 101 update: KRASG12C + PMab with 30% RR, 93% DCR, PFS=5.7M and med OS = NE after median F/U > 8M. @Amgen @myESMO #CRCSM #colorectalcancer #cancer #CancerResearch #clinicaltrials

[Arndt Vogel @ArndtVogel]

🔥New options that are explored in KRAS G12C #colorectalcancer 🔥 presented by Elena Elez at #ESMO22

@myESMO @OncoAlert

[Arndt Vogel @ArndtVogel]

🔥 CodeBreaK 100: Update on sotorasib & panitumumab in KRASG12C #colorectal cancer 🔥

✅40 pts in ≥2nd line
👉ORR 30%, DCR 90%, DOT 5.9 mo, PFS 5.7 mo, mOS nr
👉TRAE 3°: 23%
💪 intersting data in mCRC -> phase-3 awaited

@myESMO @OncoAlert

[Arndt Vogel @ArndtVogel]

🔥 KRYSTAL-1: Update on adagrasib +/- cetuximab in KRASG12C #colorectal cancer 🔥

✅ 44 pts Ada: ORR 19%, DCR 86%, DOR 4.3, PFS ws 5.6
✅32 pts ada & cetux; ORR 46%, DCR 100%, DOR 7.6, PFS 6.9, mOS 13.4
💪 new options in mCRC

@myESMO @OncoAlert

[Dr. Cathy Eng @CathyEngMD]

#ESMO22: Phase 3 Randomized HIPECT4 being presented for surgery +\- HIPEC w/MMC for T4N0-2M #colorectalcancer ⬆️local control but ⛔️ for DFS and ⛔️ OS. @oncoalert @VUMC_Cancer @VUMCHemOnc #colorectalcancer #cancer #crcsm #clinicalresearch #clinicaltrials #CancerResearch

[Dr. Cathy Eng @CathyEngMD]

#ESMO22: NICHE-2 @MyriamChalabi for tx naive dMMR #colorectalcancer, nonmetastatic, demonstrates > 95% major path response after short term #Immunotherapy treatment. Look at these waterfall plots! 👏🏻 #crcsm #colorectalcancer #cancer #CancerResearch #clinicalresearch @myESMO

[Lizzy Smyth @LizzySmyth1]

🔥🔥 TdXD as effective in non-Asian population compared to Asian 🔥🔥

DG02 Trial results @ #ESMO22

➡️ ORR 41.8%
➡️ mOS > 12.1 months

Should we have European license?

Great discussion by @FlorianLordick @myESMO

[Raghav Sundar @sundar__raghav]

Pushing the frontier in a difficult-to-treat disease: peritoneal carcinomatosis. @AndreaCercek highlights the importance of systemic therapy. Kudos to the HIPECT4 team for completing a randomized trial. We need to understand the biology of this disease better to beat it #ESMO2022

[Joseph Chao @JoeChaoMD]

@pashtoonkasi @SalemGIOncDoc @NCCN @JAMAOnc I’m a bit biased for chemo + anti-PD-1 1L in MSI-H when you look at the ORR and PFS curves, but limited by small numbers

[Pashtoon Kasi MD, MS @pashtoonkasi]

@SalemGIOncDoc From an insurance/coverage standpoint, FOLFOX➕NIVO would be a category 1 recommendation. I might use that as a regimen but skip the chemo.

I don’t think @NCCN draws a distinction for MSI-High in 1st line. But it probably should.

@JAMAOnc @JoeChaoMD
https://t.co/AigM7Ecw7f

[Journal of the @NCCN @JNCCN]

#Immunotherapy-Based Neoadjuvant Treatment of Advanced Microsatellite Instability–High #GastricCancer: A Case Series: https://t.co/LkJizWjb0f
@joechaomd @laleh_melstrom @MustafaRaoofMD @Yanghee61217641 @cityofhope #stcsm #ImmunoOnc

[Sam Klempner @KlempnerSam]

Targeting the complexity of ERBB2 biology in gastroesophageal carcinom... https://t.co/sYvr4T6Ryg. @Annals_Oncology @myESMO @BassLab_CU